/CDTX
CDTX Stock - Cidara Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$220.80+0.20%
+$0.45 (+0.20%) • Dec 19
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-28.1%upside
Target: $158.76
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CDTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$218.59 – $223.01
TARGET (TP)$158.79
STOP LOSS$203.14
RISK/REWARD1:-3.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.46
52W High$221.20
52W Low$15.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.27M | $23.28M | $64.45M | $49.57M | $12.07M |
| Gross Profit | $1.27M | $-13,480,000 | $64.45M | $-23,515,000 | $12.07M |
| Gross Margin | 100.0% | -57.9% | 100.0% | -47.4% | 100.0% |
| Operating Income | $-176,102,000 | $-27,060,000 | $-33,503,000 | $-42,255,000 | $-71,849,000 |
| Net Income | $-169,827,000 | $-22,931,000 | $-33,584,000 | $-42,467,000 | $-72,111,000 |
| Net Margin | -13319.8% | -98.5% | -52.1% | -85.7% | -597.6% |
| EPS | $-26.75 | $-5.25 | $-9.61 | $-16.20 | $-36.03 |
Company Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
71%
Hold / Neutral
2
29%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish2 Neutral/Bearish
Price Targets
$81
Average Target
↓ 63.3% Downside
Now
$24
Low
$81
Average
$200
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 17th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | - |
| November 17th 2025 | JP Morgan | Downgrade | Neutral | - |
| November 17th 2025 | Morgan Stanley | Downgrade | Equal Weight | - |
| October 16th 2025 | Morgan Stanley | Initiation | Overweight | $190 |
| October 10th 2025 | JP Morgan | Initiation | Overweight | $200 |
| June 18th 2025 | H.C. Wainwright | Resumed | Buy | $41 |
| March 12th 2025 | Citizens JMP | Initiation | Mkt Outperform | $46 |
| January 27th 2025 | Cantor Fitzgerald | Resumed | Overweight | - |
| December 13th 2024 | RBC Capital Mkts | Initiation | Outperform | $34 |
| November 8th 2024 | Guggenheim | Initiation | Buy | $33 |
| August 14th 2024 | H.C. Wainwright | Upgrade | Buy | $24 |
Earnings History & Surprises
CDTXBeat Rate
44%
Last 18 quarters
Avg Surprise
-107.3%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$-1.43
Q4 2025
EPS Surprise History
Q1 24
-90.0%
$-0.19vs$-0.10
Q2 24
-300.0%
$-0.80vs$-0.20
Q3 24
+48.0%
$-2.05vs$-3.94
Q4 24
+54.4%
$-2.38vs$-5.22
Q1 25
-1.9%
$-5.38vs$-5.28
Q2 25
+69.5%
$-1.66vs$-5.45
Q3 25
+11.8%
$-1.65vs$-1.87
Q4 25
-6.7%
$-1.43vs$-1.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-1.36 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.34 | $-1.43 | -6.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.87 | $-1.65 | +11.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-5.45 | $-1.66 | +69.5% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-5.28 | $-5.38 | -1.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-5.22 | $-2.38 | +54.4% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-3.94 | $-2.05 | +48.0% | ✓ BEAT |
Q2 2024 | Apr 22, 2024 | $-0.20 | $-0.80 | -300.0% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.10 | $-0.19 | -90.0% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-2.80 | $-1.80 | +35.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.60 | $-2.80 | -75.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $1.20 | $0.60 | -50.0% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.20 | $-3.80 | -1800.0% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $6.00 | $3.40 | -43.3% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-5.60 | $-3.80 | +32.1% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-5.20 | $-5.40 | -3.8% | ✗ MISS |
Q1 2022 | Mar 7, 2022 | $-6.60 | $-5.20 | +21.2% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-7.40 | $-7.40 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-5.40 | $3.60 | +166.7% | ✓ BEAT |
Latest News
Reported Earlier: 'Merck Seeks Up to $8 Billion in US Bond Sale Tied to Cidara Deal' - Bloomberg News
➖ NeutralBenzinga•Dec 1, 2025, 02:55 PM•Also:
Cidara Therapeutics Reaches Target Enrollment Of Phase 3 ANCHOR Trial Evaluating CD388
📈 PositiveBenzinga•Nov 24, 2025, 01:08 PM
Guggenheim Downgrades Cidara Therapeutics to Neutral
➖ NeutralBenzinga•Nov 18, 2025, 02:06 PM
HC Wainwright & Co. Downgrades Cidara Therapeutics to Neutral
➖ NeutralBenzinga•Nov 14, 2025, 07:34 PM
Needham Downgrades Cidara Therapeutics to Hold
➖ NeutralBenzinga•Nov 14, 2025, 06:52 PM
Cidara Therapeutics shares are trading higher after Merck agreed to acquire the company for $221.50 per share in a $9.2 billion cash deal.
📈 PositiveBenzinga•Nov 14, 2025, 12:18 PM•Also:
Merck Bulks Up Respiratory Portfolio With Cidara's Late-Phase, Strain-Agnostic Influenza Antiviral Cd388
📈 PositiveBenzinga•Nov 14, 2025, 11:48 AM•Also:
Merck To Acquire Cidara Therapeutics For $221.50 Per Share In Approximately $9.2B Cash Deal
📈 PositiveBenzinga•Nov 14, 2025, 11:47 AM•Also:
Financial Times Reported Merck Nears $9.2B Deal For Cidara
📈 PositiveBenzinga•Nov 14, 2025, 11:02 AM•Also:
'Merck Nears $9.2Bn Deal For Flu-Prevention Biotech Cidara' - FT
📈 PositiveBenzinga•Nov 14, 2025, 09:21 AM•Also:
Merck seen nearing acquisition of Cidara Therapeutics in deal potentially above $3.3 billion
📈 PositiveSeeking Alpha•Nov 14, 2025, 07:18 AM•Also:
RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $145
📈 PositiveBenzinga•Nov 7, 2025, 06:48 PM
Needham Maintains Buy on Cidara Therapeutics, Raises Price Target to $135
📈 PositiveBenzinga•Nov 7, 2025, 10:12 AM
UPDATE: Cidara Therapeutics Q3 Adj. EPS $(1.43) Misses $(1.35) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 10:55 PM
Cidara Therapeutics Q3 EPS $(3.10) Misses $(1.33) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:25 PM
Cidara Therapeutics Presents Data On CD388 Candidate At European Scientific Working Group On Influenza In Spain
➖ NeutralBenzinga•Oct 23, 2025, 12:03 PM
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $150 Price Target
📈 PositiveBenzinga•Oct 21, 2025, 04:28 PM
Cidara Therapeutics Releases New Phase 2b Clinical Data From Its Navigate Study Showing Its Influenza Preventative Candidate CD388 Demonstrated Up To 76.1% Efficacy Against Influenza A And B In Healthy, Unvaccinated Adults
📈 PositiveBenzinga•Oct 21, 2025, 12:10 PM
Morgan Stanley Initiates Coverage On Cidara Therapeutics with Overweight Rating, Announces Price Target of $190
📈 PositiveBenzinga•Oct 16, 2025, 01:07 PM
Cidara Therapeutics shares are trading higher after the company announced it will present CD388 NAVIGATE Phase 2b influenza data at ESWI 2025. Also, JP Morgan initiated coverage on the stock with an Overweight rating and announced a $200 price target.
📈 PositiveBenzinga•Oct 10, 2025, 01:02 PM•Also:
Frequently Asked Questions about CDTX
What is CDTX's current stock price?
Cidara Therapeutics, Inc. (CDTX) is currently trading at $220.80 per share. The stock has moved +0.20% today.
What is the analyst price target for CDTX?
The average analyst price target for CDTX is $158.79, based on 1 analyst.
What sector is Cidara Therapeutics, Inc. in?
Cidara Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CDTX's market cap?
Cidara Therapeutics, Inc. has a market capitalization of $5.60 billion, making it a mid-cap company.
Does CDTX pay dividends?
No, Cidara Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
AGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CPRX
Catalyst Pharmaceuticals, Inc.
$23.74
Mkt Cap: $2.9B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to CDTX for comparison